| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8212986 | International Journal of Radiation Oncology*Biology*Physics | 2017 | 8 Pages |
Abstract
PIF is common after treatment of LACC and is mainly seen in patients aged >50Â years. Our data indicate that PIFs are not related to lymph node boosts but rather to dose and volume associated with irradiation of the elective pelvic target. Reducing the prescribed elective dose from 50 to 45Â Gy may reduce the risk of PIF considerably.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Anne MD, Erik Morre MD, DMSc, Lisbeth MD, PhD, Esben PhD, Lars MD, PhD, Jacob Chr. MD, DMSc, Kari PhD,